Shots:

• Bayer to take care of subsequent clinical development and commercialization. Evotec to receive €6.5M up front- €10M research payments over five years- up to €330M milestones pre-clinical and sales milestones- royalties on sales
• The companies will supply the drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options. Additionally- the deal will have access to targets partnership between Celmatix and Evotec in Oct 2019  
• In 2012- Bayer and Evotec signs a five-year multi-target agreement for three clinical and one pre-clinical drug candidates currently involved to treat endometriosis. Additionally- in 2016- the companies collaborated to develop therapies for kidney disease

Click here to read full press release/ article | Ref: Bayer | Image: Twitter